Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Wendy G. Arsenault x
  • Refine by Access: All Content x
Clear All Modify Search

A 12-year-old 2.5-kg sexually intact male Pomeranian mix was presented for pacemaker interrogation 2 weeks following placement of a transvenous VVI pacemaker with active lead fixation. The pacemaker was placed following episodes of collapse secondary to third-degree atrioventricular (AV) block. Examination, radiographic, and echocardiographic findings prior to pacemaker implantation were consistent with stage B1 chronic degenerative valve disease. The dog was bright and alert on presentation and was reported to be asymptomatic by the owner, other than frequent head shaking since surgery. The owner reported a heart rate at home ranging from 60 to 80 beats/min. On physical examination,

Restricted access
in Journal of the American Veterinary Medical Association


Objective—To determine the pharmacokinetics of carvedilol administered IV and orally and determine the dose of carvedilol required to maintain plasma concentrations associated with anticipated therapeutic efficacy when administered orally to dogs.

Animals—8 healthy dogs.

Procedures—Blood samples were collected for 24 hours after single doses of carvedilol were administered IV (175 µg/kg) or PO (1.5 mg/kg) by use of a crossover nonrandomized design. Carvedilol concentrations were detected in plasma by use of high-performance liquid chromatography. Plasma drug concentration versus time curves were subjected to noncompartmental pharmacokinetic analysis.

Results—The median peak concentration (extrapolated) of carvedilol after IV administration was 476 ng/mL (range, 203 to 1,920 ng/mL), elimination half-life (t1/2) was 282 minutes (range, 19 to 1,021 minutes), and mean residence time (MRT) was 360 minutes (range, 19 to 819 minutes). Volume of distribution at steady state was 2.0 L/kg (range, 0.7 to 4.3 L/kg). After oral administration of carvedilol, the median peak concentration was 24 µg/mL (range, 9 to 173 µg/mL), time to maximum concentration was 90 minutes (range, 60 to 180 minutes), t1/2 was 82 minutes (range, 64 to 138 minutes), and MRT was 182 minutes (range, 112 to 254 minutes). Median bioavailability after oral administration of carvedilol was 2.1% (range, 0.4% to 54%).

Conclusions and Clinical Relevance—Although results suggested a 3-hour dosing interval on the basis of MRT, pharmacodynamic studies investigating the duration of β-adrenoreceptor blockade provide a more accurate basis for determining the dosing interval of carvedilol. (Am J Vet Res 2005;66:2172–2176)

Full access
in American Journal of Veterinary Research